<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0100022'>Movement disorders</z:hpo> (MDs), particularly <z:hpo ids='HP_0002072'>chorea</z:hpo>, may be the presenting neurological complication of <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE) and the <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS), but the association is not often initially recognized </plain></SENT>
<SENT sid="1" pm="."><plain>Current evidence suggests an autoimmune mechanism related to <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> in these two conditions, although the antigenic target within the central <z:mp ids='MP_0008912'>nervous</z:mp> system has not yet been identified </plain></SENT>
<SENT sid="2" pm="."><plain>Based on a comprehensive review of the literature, this article summarizes the current knowledge on MDs in SLE and APS </plain></SENT>
<SENT sid="3" pm="."><plain>A high index of suspicion is required to make an early diagnosis and initiate appropriate treatment to provide symptomatic relief and to prevent other systemic complications related to the autoimmune process </plain></SENT>
</text></document>